Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Price T Rowe Associates Inc. MD Reduces Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
11:00am, Saturday, 20'th Nov 2021 Transcript Daily
Price T Rowe Associates Inc. MD trimmed its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 10.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 76,255 shares of the biopharmaceutical companys stock after selling 9,286 shares during the quarter. Price []
Madrigal Pharmaceuticals (MDGL) Presents At The Virtual Lever Meeting 2021 - Slideshow
07:53pm, Friday, 19'th Nov 2021 Seeking Alpha
Man Group plc Buys 4,600 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
01:46pm, Wednesday, 17'th Nov 2021 Dakota Financial News
Man Group plc increased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 32.6% in the second quarter, according to its most recent filing with the SEC. The fund owned 18,700 shares of the biopharmaceutical companys stock after acquiring an additional 4,600 shares during the period. Man Group plc owned about 0.11% of Madrigal []
Madrigal: Major Catalyst Coming Up
04:35pm, Sunday, 14'th Nov 2021
Madrigal announced data at AASLD that was published earlier. They have their most important catalyst coming up.
In recognition of Liver Awareness Month, Madrigal and Fatty Liver Foundation Ring Nasdaq Closing Bell to Increase Awareness of NAFLD/NASH In recognition of Liver Awareness Month, Madrigal and Fatty Li
Madrigal Pharmaceuticals Reports 2021 Second Quarter Financial Results and Provides Corporate Update
06:50am, Thursday, 05'th Aug 2021
CONSHOHOCKEN, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reports today its second quarter 2021 financial results and provides a summary of corporate accomplish
Robert Waltermire Joins Madrigal Pharmaceuticals as Chief Pharmaceutical Development Officer
06:50am, Monday, 02'nd Aug 2021
CONSHOHOCKEN, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and fatty liver diseases with
Here's Why Madrigal (MDGL) is Poised for a Turnaround After Losing 14.9% in 4 Weeks
11:30am, Tuesday, 27'th Jul 2021
Madrigal (MDGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
CONSHOHOCKEN, Pa., July 13, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today its first patient dosed in a planned 52-week open label active treatment extension stu
Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom
06:50am, Wednesday, 30'th Jun 2021
CONSHOHOCKEN, Pa., June 30, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today achievement of the planned target enrollment in the Phase 3 clinical trial, MAESTRO-NA
CONSHOHOCKEN, Pa., June 25, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), today announced the presentation of positive clinical data from the open-label portion of its ongoing
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences
06:50am, Tuesday, 08'th Jun 2021
WEST CONSHOHOCKEN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical- stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and
20 Short Ideas With Super-Weak Momentum
10:39am, Monday, 31'st May 2021
Often, weak stocks going into a market correction or bear move will decline faster than the main indexes. I have listed 20 stocks/ETFs out of a 4000+ sort universe experiencing a rush of selling since
Madrigal Pharmaceuticals to Participate in UBS Global Healthcare Virtual Conference
09:38am, Friday, 21'st May 2021
WEST CONSHOHOCKEN, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and f
Alex Howarth Joins Madrigal Pharmaceuticals as Chief Financial Officer
06:50am, Tuesday, 18'th May 2021
WEST CONSHOHOCKEN, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for cardio-metabolic and f
